Black Diamond Therapeutics Inc logo

BDTX - Black Diamond Therapeutics Inc News Story

$24.83 -0.7  -2.6%

Last Trade - 14/04/21

Sector
Healthcare
Size
Mid Cap
Market Cap £670.3m
Enterprise Value £441.1m
Revenue £n/a
Position in Universe 2893rd / 6848

Black Diamond Therapeutics Provides Update on GBM Program and Presents Pre-Clinical Data at the 2020 SNO Annual Meeting

Fri 20th November, 2020 12:45pm
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20201120:nGNXcbFX0Y

* BDTX-1535 nominated as development candidate with IND-enabling studies
underway

* Pre-clinical data support novel and differentiated approach in GBM
CAMBRIDGE, Mass. and NEW YORK, Nov. 20, 2020 (GLOBE NEWSWIRE) --  Black
Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine
company pioneering the discovery and development of small molecule,
tumor-agnostic therapies, today announced the nomination of BDTX-1535 as the
Company’s development candidate for the treatment of glioblastoma multiforme
(GBM), as well as the commencement of Investigational New Drug (IND)-enabling
studies.

Additionally, Black Diamond Therapeutics today announced a presentation at the
2020 Society for Neuro-Oncology Annual Meeting (SNO) of the pre-clinical data
for BDTX-1535 and the biological rationale for a MasterKey approach to
treating GBM patients whose tumors harbor allosteric oncogenic mutations in
epidermal growth factor receptor (EGFR).

“These pre-clinical data demonstrate the achievement of our program’s key
design principles, including potent and selective inhibition of the family of
EGFR variants implicated in GBM and penetration of the blood-brain barrier,
and further support our ability to develop a novel and differentiated
candidate for the treatment of this disease,” said Elizabeth Buck, Ph.D.,
Executive Vice President, Discovery and Translational Sciences at Black
Diamond Therapeutics. “This profile, coupled with the in vivo data that
showed tumor growth inhibition in intracranial patient-derived xenograft (PDX)
tumor models expressing allosteric EGFR mutants, supports the potential for
BDTX-1535 to meaningfully transform the treatment paradigm for patients with
GBM.”

GBM tumors express a family of allosteric oncogenic EGFR variants that often
appear together in GBM and, as shown by the Company’s pre-clinical work,
must all be effectively inhibited to secure a meaningful anti-tumor response.
In cell-based assays, BDTX-1535 achieved potent MasterKey inhibition of all
members of the family of oncogenic EGFR variants expressed in GBM with
selectivity v. wild-type-EGFR (WT-EGFR). Additionally, in mouse models,
BDTX-1535 demonstrated a pharmacokinetic profile that supports its ability to
penetrate the blood-brain barrier. BDTX-1535 achieved complete and sustained
inhibition of the phosphorylated state of EGFR in mouse models bearing Ba/F3
allosteric EGFR mutants, as well as tumor growth inhibition in mouse models
bearing intracranial PDX tumors expressing allosteric EGFR mutants.

“Glioblastoma places an enormous burden on patients and their families, and
we’re encouraged by these pre-clinical data that support BDTX-1535’s
potential to improve treatment options for those impacted by GBM. The
advancement of BDTX-1535 into early development is a critical step in our
pursuit of a truly innovative approach for the treatment of this devastating
disease,” said David M. Epstein, Ph.D., President and Chief Executive
Officer of Black Diamond Therapeutics. “We remain committed to the broad
deployment of our proprietary MAP platform to produce novel MasterKey
inhibitor therapies for a range of genetically defined diseases.”

The presentation from the SNO 2020 meeting is available on the “Scientific
Presentations and Publications” section of the Black Diamond Therapeutics
website.

About Black Diamond Therapeutics

Black Diamond Therapeutics is a precision oncology medicine company pioneering
the discovery of small molecule, tumor-agnostic therapies. Black Diamond
targets undrugged mutations in patients with genetically defined cancers.
Black Diamond is built upon a deep understanding of cancer genetics, protein
structure and function, and medicinal chemistry. The Company’s proprietary
technology platform, Mutation-Allostery-Pharmacology (MAP) platform, is
designed to allow Black Diamond to analyze population-level genetic sequencing
data to identify oncogenic mutations that promote cancer across tumor types,
group these mutations into families, and develop a single small molecule
therapy in a tumor-agnostic manner that targets a specific family of
mutations. Black Diamond was founded by David M. Epstein, Ph.D. and Elizabeth
Buck, Ph.D., and, beginning in 2017, together with Versant Ventures, began
building the MAP platform and chemistry discovery engine. For more
information, please visit www.blackdiamondtherapeutics.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995. Because such statements
are subject to risks and uncertainties, actual results may differ materially
from those expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding the continued
development and advancement of BDTX-1535 in IND-enabling studies. Any
forward-looking statements in this statement are based on management’s
current expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. Risks that contribute to the uncertain nature of the
forward-looking statements include: the success, cost, and timing of the
Company’s product candidate development activities and planned IND-enabling
and clinical trials, the Company’s ability to execute on its strategy,
regulatory developments in the United States, the Company’s ability to fund
operations, and the impact that the current COVID-19 pandemic will have on the
Company’s clinical trials, supply chain, and operations, as well as those
risks and uncertainties set forth in its 2019 annual report on Form 10-K filed
with the United States Securities and Exchange Commission and its other
filings filed with the United States Securities and Exchange Commission. All
forward-looking statements contained in this press release speak only as of
the date on which they were made. The Company undertakes no obligation to
update such statements to reflect events that occur or circumstances that
exist after the date on which they were made.

Contacts:

For Investors:
Natalie Wildenradt
investors@bdtherapeutics.com

For Media:
Kathy Vincent
(310) 403-8951
media@bdtherapeutics.com



(https://www.globenewswire.com/NewsRoom/AttachmentNg/b8da4d92-789b-4f0a-a1e2-2739af370155)



GlobeNewswire, Inc. 2020
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.